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Abstract: Multiple sclerosis (MS) is a central nervous system chronic inflammatory disease 
that is characterized by an extensive and complex immune response. Scientific advances have 
occurred in immunology, pathophysiology, and diagnostic and clinical assessment tools, and 
recent discovery of unique therapeutic targets has spurred numerous Phase II and Phase III 
clinical trials. Reductions in MS relapse rates and improvements in T2 or gadolinium-enhancing 
lesion burdens have been reported from Phase III trials that include fingolimod, alemtuzumab, 
cladribine, and rituximab. Promising Phase II trial data exist for teriflunomide, daclizumab, 
laquinimod, and fumarate. The optimism created by these favorable findings must be tempered 
with evaluation of the adverse effect profile produced by these new agents. Given the discovery 
of progressive multifocal leukoencephalopathy with the use of natalizumab, ongoing vigilance 
for rare and life-threatening reactions due to new agents should be paramount. Patients with 
MS often experience difficulty with ambulation, spasticity, and cognition. Recent clinical trial 
data from two Phase III dalfampridine-SR trials indicate certain patients receive benefits in 
ambulation. This article provides an overview of data from clinical trials of newer agents of 
potential benefit in MS.
Keywords: multiple sclerosis, Phase II trials, Phase III trials, progressive multifocal 
  leukoencephalopathy, monoclonal antibody
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease associated with central 
nervous system (CNS) demyelination. MS exhibits an unpredictable and variable 
clinical course, making treatment challenging. Discoveries in immunology, magnetic 
resonance imaging (MRI) and diagnostics, early treatment options, and development 
of biological agents have improved the prospects for many MS patients. This article 
discusses recent advances in MS immunology, current and experimental therapies, 
and future targets for drug development.
Epidemiology
MS is typically diagnosed in the third or fourth decade of life with only 5%–10% of dis-
ease onset occurring in individuals aged less than 10 or more than 50 years old.1 Women 
are affected approximately twice as often as males who are more likely diagnosed later 
in life and have a progressive course of disease. Individuals living further from the 
equator are more commonly affected, with people living in Europe, southern   Australia, 
and the middle of North America at greatest risk.1–3 The criteria for diagnosing MS have 
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(2005) has generally replaced the older Schumacher and 
Poser criteria.4,5 McDonald criteria include clinical, paraclini-
cal, and laboratory evidence of demyelinating inflammatory 
lesions disseminated in space and time. MRI, cerebrospinal 
fluid analysis, and visual-evoked potentials assist in diag-
nosis. A consensus statement by an international panel of 
experts includes guidelines for differential diagnosis of MS 
and clinically isolated syndrome (CIS).6
A first episode of a neurological sign or symptom 
consistent with MS, caused by demyelination, is defined as 
a CIS. Optic nerve dysfunction, diplopia, bladder and bowel 
dysregulation, ataxia, limb sensory dysfunction, and pyramidal 
tract abnormalities represent some hallmark CIS signs and 
symptoms.7 CIS patients with concurrent MRI abnormalities 
are at higher risk for eventually acquiring the diagnosis of 
clinically definite multiple sclerosis.8 Several major placebo-
controlled clinical trials, ETOM,9 CHAMPS,10 BENEFIT,11 
and PreCISe,12 have shown that interferon (IFN) β-1a (Rebif®; 
EMD Serono, Inc., Rockland, MA, USA) (Avonex®; Biogen 
Idec, Cambridge, MA, USA), IFN β-1b (Betaseron®; Bayer 
Healthcare Pharmaceuticals, Inc., Montville, NJ, USA), or 
glatiramer acetate (Copaxone®; TEVA Neuroscience, Inc., 
Kansas City, MO, USA) therapy in CIS patients postpones 
the time to clinically definite multiple sclerosis for some. A 
3-year extension of the BENEFIT13 study and a 5-year exten-
sion of the CHAMPS study, CHAMPION,14 have confirmed 
benefits of early treatment.
MS typically follows a relapsing and remitting course 
in its early stages; patients experience symptomatic attacks 
or exacerbations, which occur for a period of time and then 
resolve. This presentation occurring in 80%–85% of patients is 
classified as relapsing–remitting multiple sclerosis (RRMS).1–3 
The typical course for RRMS includes initial stages of relapse 
with full or partial recovery, then relapse with persistent defi-
cit, and eventually secondary progressive disease (Figure 1).3 
Approximately 50% of individuals diagnosed with RRMS 
will enter a secondary progressive MS (SPMS) phase after 
10 years,15 whereas 15%–20% of patients will experience the 
primary progressive form of MS (PPMS) at onset.
Prognosis in MS varies significantly. Approximately 10% 
of patients function well for 20 or more years.2 However, 
death occurs within months in rare cases of PPMS.3 Life 
expectancy after diagnosis is ∼25 years, and most patients 
die of other causes.3 Patients with optic neuritis, brain-stem 
dysfunction, incomplete transverse myelitis, and motor 
involvement with gait and coordination dysfunction have a 
more negative prognosis. In contrast, patients with sensory or 
visual symptoms as a dominant neurological sign have a more 
positive prognosis. Women, younger patients, and those with 
RRMS disease who experience a more complete recovery 
after exacerbations have a better prognosis, whereas patients 
with PPMS fare worse.2,5 Discussed as early as the 1950s,16 
data from recent epidemiological studies suggest pregnancy 
has a ‘protective’ effect resulting in fewer MS relapses. It was 
hypothesized that increased estrogen levels that are normal 
during pregnancy modulate MS response.
Quality of life measures/clinical 
assessment tools
Several validated assessment instruments have been used to 
document MS baseline disability and disease progression. 
The Expanded Disability Status Scale (EDSS) was intro-
duced in 1983 and yields scores ranging from 0 (normal 
neurological exam) to 10 (death) in 0.5 numeric increments. 
EDSS scores ,3.0, 3.0–5.0, and .5.0 represent mild, 
moderate, and severe disability, respectively. Important 
limitations associated with the EDSS include the need for 
physicians to administer the test, nonlinear scores, rater 
subjectivity at EDSS scores less than 3, and excessive weight-
ing of ambulation versus cognition and upper extremity   
function.17
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Figure 1 Natural history of MS. Four clinical patterns are recognized by international 
consensus.  Approximately  85%  of  patients  experience  RRMS,  characterized  by 
the abrupt start of symptoms and acute episodes of worsening (exacerbations or 
relapses) with complete or partial recovery. Between these episodes, patients may 
be clinically stable, may experience gradual progression of disability, or may undergo 
a combination of both. Approximately 50% of patients with RRMS convert to SPMS 
within 10 years of disease onset. The secondary progressive phase is characterized by 
gradual progression of disability with or without superimposed relapses. in contrast, 
patients with PPMS (∼10% of patients with MS) experience gradual progression 
of disability from onset without superimposed relapses. Patients with progressive 
relapsing MS experience gradual progression of disability from disease onset, later 
accompanied by one or more relapses; this clinical pattern affects ∼5% of patients. 
An important conceptual development in the understanding of MS pathogenesis has 
been the compartmentalization of the mechanistic process into two distinct but 
overlapping and connected phases, inflammatory and neurodegenerative. Axonal 
loss begins most likely at disease onset and accumulates. Conversion of relapsing–
remitting to secondary progressive occurs once axon loss surpasses the capacity of 
the CNS to compensate for loss of function. Copyright © 2006, elsevier. Adapted 
with  permission  from  Hauser  SL,  Oksenberg  JR.  The  neurobiology  of  multiple 
sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52(1):61–76.15
Abbreviations: CNS, central nervous system; RRMS, relapsing–remitting multiple 
sclerosis; SPMS, secondary progressive multiple sclerosis; PPMS, primary progressive 
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The Multiple Sclerosis Functional Composite (MSFC) 
assessment tool was developed in 1994 by a National 
Multiple Sclerosis Society task force. The MSFC tests 
upper extremity dexterity with a timed nine-hole peg test, 
timed walking speed over 25 feet, and cognition via Paced 
Auditory Serial Addition Test (PASAT). The MSFC has 
demonstrated construct validity among different MS patient 
populations and concurrent validity with EDSS scores and 
MRI findings.17
Outcome measures in most MS clinical trials include 
relapse rates, appearance of new or expansion of existing 
lesions, or change in other surrogate markers of inflamma-
tion. Historically, health-related quality of life measures were 
ignored or given secondary consideration, and few clinical 
trials were ‘powered’ to detect significant differences in 
health-related quality of life measures. Medical Outcomes 
Study Short Form-36, Functional Status Questionnaire, and 
the Sickness Impact Profile are some of the instruments used 
in MS studies. These general instruments have broad appli-
cability, making comparison possible to other individuals 
with serious medical illnesses. Multiple Sclerosis Quality 
of Life Inventory, Multiple Sclerosis Quality of Life-54, 
Functional Assessment of Multiple Sclerosis, Leeds Multiple 
Sclerosis Quality of Life scale, and Multiple Sclerosis Impact 
Scale-29 are reliable and validated instruments specific 
for MS. Miller et al have recently completed an excellent 
review of the advantages and disadvantages of these MS   
instruments.18
Pathogenesis
MS plaques result from an altered immune response initiated 
in the periphery but ultimately manifested on myelin, glial 
cells, dendrites, and axons of the CNS. The exact etiology 
of MS is unknown, but evidence suggests an environmental 
trigger in a genetically susceptible individual leads to an 
altered immune response directed against self that results 
in inflammation, demyelination, neurodegeneration, and 
dysfunctional neuronal repair. Immunologic responses in 
MS are characterized by an intricate and extensive cascade of 
events. Much of our understanding of processes that initiate 
altered immune response, myelin destruction, chronic axonal 
damage, and dysfunctional repair in MS has been elucidated 
by use of animal models. Experimental autoimmune enceph-
alopathy (EAE) and mice knockout models, which share 
similarities to MS in humans, have played an essential role 
in unraveling elements of the immunologic cascade.19   Various 
animal models exist that express similarities to human 
d  iseases of optic neuritis,20 RRMS, and chronic progressive 
MS.21 Gold et al have recently completed an excellent review 
article documenting seven decades of animal model use in 
MS research.22
Undoubtedly, critical information will continue to be 
gleaned from ongoing work with animal models. However, 
many scientists and practitioners believe that new biomarkers 
from individuals with MS are required. New biomarkers 
should be sought to aid in prognosis or augment existing 
means of patient stratification prior to entry in novel clinical 
trials.23
Over the past 50 years, numerous viruses have been 
implicated as the ‘infectious’ component for initiating the 
inflammatory responses typical of MS in genetically pre-
disposed patients. At various times, herpes simplex viruses 
1 or 2, cytomegalovirus, measles, mumps, rubella, and 
Epstein–Barr virus have been promoted as candidates. The 
viral infection theory involves nuanced discussions related to 
geographical variation, ‘hygiene’ hypothesis, cerebrospinal 
fluid titers, viral reactivation and MS exacerbations, and 
immunoassay limitations that are beyond the scope of this 
review. The potential role of infection in MS has recently 
been reviewed.24
Clustering of MS in families and certain ethnic groups 
and results from monozygotic and dizygotic twin studies 
provide evidence of a genetic link. Linkage studies have iden-
tified the human leukocyte antigen class II locus in the major 
histocompatibility complex (MHC) region on chromosome 
6p21 as being significant but accounting for only a portion 
of MS susceptibility.25 Sophisticated mapping techniques of 
MS patients using single nucleotide polymorphisms in genes 
have identified additional MS susceptibility associated with 
a gene encoding a subunit of high-affinity interleukin-2 
  receptor (IL2RA), also known as CD25, and possibly genes 
for IL-7 receptor (IL7R).26 Oksenberg and colleagues have 
published an excellent review of this topic.27 Data mining of 
extensive brain plaque libraries from MS patients, compared 
to data from normal controls, have yielded other important 
areas of investigation. Such comparisons have led to investi-
gations of osteopontin (OPN), myelin basic protein (MBP), 
IFN-γ, and IL-12.28
Pathophysiology
Molecular mimicry or bystander activation are two popular 
theories used to explain how environmental triggers lead to 
altered autoimmunity.29 Molecular mimicry involves viral 
pathogens or other foreign antigens that share antigenic 
determinants similar to host cells triggering T-cell   activation.28 
Numerous proteins from herpes, measles, influenza, and Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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other viruses share amino acid homologies to MBP, making 
them attractive candidates as mimics.15 Bystander activation 
postulates viral or bacterial infections cause tissue destruction 
exposing self-antigens. These self-antigens in the presence 
of cytokines, chemokines, or interleukins lead to enhanced 
antigen cell presentation, T-cell activation and proliferation, 
with subsequent, targeted response to MBP, proteolipid 
protein, and myelin oligodendrocyte glycoprotein (MOG).29 
Whether initiated by a molecular mimic or exposure of 
autoantigens, the subsequent altered response of the immune 
system in MS is complex. The complexity of response in MS 
can, in part, be described by events that occur in the peripheral 
compartment, cellular migration across the blood–brain barrier 
(BBB), and events isolated within the CNS. Another layer 
of complexity of MS results from the activation and interac-
tion of the innate and adapted immune systems. Paramount 
events in the periphery consist of T-cell activation, tethering, 
rolling, and adhesion, facilitated by integrin expression on 
activated T cells and interaction with its upregulated ligand 
vascular cellular adhesion molecule-1 (VCAM-1), expressed 
on the endothelium of blood vessels of the CNS. T-cell 
transmigration across the BBB and further trafficking within 
the CNS are aided by matrix metalloproteinases. Numerous 
immune and antibody-mediated events occur in the CNS. 
Astrocytes, microglia, and macrophages act as antigen-
presenting cells that, along with MHC proteins, process MS 
antigen generating CD4+ effector T cells capable of expressing 
Th1 or Th2 cell phenotypes. Subsequent exposure to tumor 
necrosis factor-α (TNF-α), IFN-γ, or other costimulants causes 
restricted cytotoxic CD8+ T-cell upregulation. Th2 cells, under 
the influence of various interleukins, can activate B cells 
that initiate antibody production directed against host tissue   
(see Figure 2).
Considerable heterogeneity of cellular components from 
active MS lesions exists, and a classification scheme of 
four distinct lesion patterns has been developed. This clas-
sification scheme proposes that MS shifts from an initial 
autoinflammatory disease driven by cellular and humoral 
abnormalities (Patterns I and II) to one dominated by lack 
of B- and T-cell infiltration, apoptosis, ischemia, primary 
glial damage, and sparse remyelination (Patterns III and IV) 
(see Figure 3). Conceptually, this classification scheme helps 
categorize complex immunological responses, serves to 
identify potential therapeutic targets, and may help to explain 
progression from RRMS to SPMS. However, others point out 
that rigorous, static classification schemes fail to accurately 
account for MS patients who present with multiples lesions 
in different phases.30
Figure 2 Possible mechanisms of injury and repair in MS. Genetic and environmental 
factors (including viral infection, bacterial lipopolysaccharides, superantigens, reactive 
metabolites,  and  metabolic  stress)  may  facilitate  the  movement  of  autoreactive 
T cells and demyelinating antibodies from the systemic circulation into the CNS 
through disruption of the BBB. in the CNS, local factors (including viral infection 
and  metabolic  stress)  may  upregulate  the  expression  of  endothelial  adhesion 
molecules, such as iCAM-1, vCAM-1, and e-selectin, further facilitating the entry 
of T cells into the CNS. Proteases, including matrix metalloproteinases, may further 
enhance  the  migration  of  autoreactive  immune  cells  by  degrading  extracellular-
matrix macromolecules. Proinflammatory cytokines released by activated T cells, 
such as iFN-γ and TNF-β, may upregulate the expression of cell-surface molecules 
on neighboring lymphocytes and antigen-presenting cells. Binding of putative MS 
antigens,  such  as  myelin  basic  protein,  myelin-associated  glycoprotein,  MOG, 
proteolipid protein, αβ-crystallin, phosphodiesterases, and S-100 protein, by the 
trimolecular complex – the TCR and class ii MHC molecules on antigen-presenting 
cells – may trigger either an enhanced immune response against the bound antigen 
or anergy, depending on the type of signaling that results from interactions with 
surface costimulatory molecules (eg, CD28 and CTLA-4) and their ligands (eg, B7-1 
and B7-2). Downregulation of the immune response (anergy) may result in the 
release of anti-inflammatory cytokines (IL-1, IL-4, and IL-10) from CD4+ T cells, 
leading to the proliferation of anti-inflammatory CD4+ Th2 cells. Th2 cells may send 
anti-inflammatory  signals  to  the  activated  antigen-presenting  cells  and  stimulate 
pathologic or repair-enhancing antibody-producing B cells. Alternatively, if antigen 
processing results in an enhanced immune response, proinflammatory cytokines 
(eg, iL-12 and iFN-γ) may trigger a cascade of events, resulting in the proliferation 
of proinflammatory CD4+ Th1 cells and ultimately in immune-mediated injury to 
myelin and oligodendrocytes. Multiple mechanisms of immune-mediated injury of 
myelin  have  been  postulated:  cytokine-mediated  injury  of  oligodendrocytes  and 
myelin; digestion of surface myelin antigens by macrophages, including binding of 
antibodies against myelin and oligodendrocytes (ie, antibody-dependent cytotoxicity); 
complement-mediated injury; and direct injury of oligodendrocytes by CD4+ and 
CD8+ T cells. This injury to the myelin membrane results in denuded axons that 
are no longer able to transmit action potentials efficiently within the CNS (loss of 
saltatory conduction). This slowing or blocking of the action potential results in the 
production of neurologic symptoms. The exposed axon segments may be susceptible 
to further injury from soluble mediators of injury (including cytokines, chemokines, 
complement, and proteases), resulting in irreversible axonal injury (such as axonal 
transection and terminal axon ovoids). There are several possible mechanisms of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Immunologic targets
Antigen processing in the peripheral compartment is 
responsible for antibody production within peripheral lymph 
nodes. Trapping activated T cells within lymph nodes would 
prevent lymphocyte egress and their subsequent transmigra-
tion to the CNS. Spingosine-1-phosphate (S1P1) receptors 
on lymphocytes are responsible for egress from peripheral 
lymph nodes. Fingolimod (FTY720) (Gilenia®; Biogen 
Idec, Cambridge, MA, USA) is a reversible S1P1 antagonist 
that has shown benefits in reducing relapse rates in RRMS   
patients.31
Integrins are a superfamily of molecules that assist 
lymphocyte trafficking from peripheral cells to numerous 
target organs. Each integrin has one or more corresponding 
ligands, and specificity for trafficking is determined by this 
partnership. α4β1 integrin is specific to CNS endothelium, 
and antagonism in EAE animal models led to blunted 
lymphocyte migration and improved clinical course of 
EAE.32 Natalizumab (Tysarbi®; Elan Pharmaceuticals, Inc., 
South San Francisco, CA, USA) is a monoclonal antibody 
directed at α4β1 integrin that has shown substantial activity 
at suppressing relapse rates in MS patients.33
During research to record the cognate receptors for the 
superfamily of integrins, OPN was discovered to bind to 
α4β1 integrin.34 OPN enhances Th1- and Th17-type cytokine 
responses in dendritic cells in EAE models and in MS.35,36 
OPN has pleotrophic effects in various animal models, 
capable of inducing relapse remission in SJL/J mice but 
also blunting recovery and promoting disease progression in 
another animal model, C57BL/6 mice.37 Data obtained during 
human transcription gene studies comparing mRNA from 
11,000 patients with MS versus results from normal brain tis-
sue identified αβ-crystallin as the most commonly transcribed 
gene while OPN was the fifth.38 Astrocytes and microglial 
cells can express OPN,38 and up regulated expression of OPN 
has been described by others in normal-appearing white mat-
ter of MS.39 Data from emerging research indicate that OPN 
regulates coagulation proteins such as fibronectin, serpin A5, 
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Figure 3 Classification of MS lesion pattern. Various cellular (macrophages and activated microglia) and humoral (antibodies and complement) immune components are 
dominating in Pattern I and II lesions. In contrast, Pattern III and IV are mainly characterized by a primary oligodendropathy with less inflammation. Type III lesions barely 
remyelinate and are similar to lesions found after hypoxic and/or toxic brain injury. Type iv lesions differ from lesion Pattern iii by increased oligodendrocyte apoptosis due 
to metabolic dysfunction.
Copyright © 2007, Bentham Science Publishers. Adapted with permission from Kleinschnitz C, Meuth SG, Kieseier BC, wiendl H. immunotherapeutic approaches in MS: 
update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets. 2007;7(1):35–63.128
Abbreviations: CD8, CD8 T cell; MF, macrophage; MOG, myelin oligodendrocyte glycoprotein; ROS, reactive oxygen species; T, T cell; TNF, tumor necrosis factor.
repair of the myelin membrane, including resolution of the inflammatory response 
followed by spontaneous remyelination, spread of sodium channels from the nodes of 
Ranvier to cover denuded axon segments and restore conduction, antibody-mediated 
remyelination,  and  remyelination  resulting  from  the  proliferation,  migration,  and 
differentiation of resident oligodendrocyte precursor cells.
Copyright © 2000, Massachusetts Medical Society. All rights reserved. Adapted with 
permission from Noseworthy JH, Lucchinetti C, Rodriguez M, weinshenker BG. 
Multiple sclerosis. N Engl J Med. 2000;343(13):938–952.2
Abbreviations:  iCAM-1,  intercellular  adhesion  molecule  1;  vCAM-1,  vascular-cell 
adhesion molecule 1; CNS, central nervous system; TNF-β, tumor necrosis factor-β; 
MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; TCR, T-cell receptor; 
MHC, major-histocompatibility-complex; Th1, type 1 helper T; Th2, type 2 helper T; 
BBB, blood–brain barrier.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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tissue factor, and thrombospondin. These coagulation proteins 
and others have been isolated from MS lesions.40 Thrombin 
has been shown to cleave OPN, which subsequently exposes 
additional α4β1 integrin binding sites.34
αβ-Crystallin is a member of the superfamily of small heat 
shock proteins. These proteins serve as molecular chaperones 
helping to maintain cellular homeostasis. Research in both 
relapsing–remitting and chronic progressive EAE models 
has shown αβ-crystallin aids in reducing generation of Th1 
and Th17 cytokines by myelin specific T cells. Pretreatment 
with recombinant αβ-crystallin protected glial cells, lowered 
clinical disease scores, and modified paralysis in EAE.41
CNS tissue destruction of myelin and axons is accom-
plished through several different antibody-dependent 
  processes, cell-mediated toxic pathways, complements, 
and macrophages.15 Autoantibodies directed against myelin 
oligodendrocyte glycoprotein, MBP, and proteolipid protein 
have been found in cerebral spinal fluid of MS patients.42 
Microglia and CNS macrophages are capable of acting as 
antigen-presenting cells for reactive T cells by expressing 
MHC class II molecules and stimulatory ligands. These cells 
cause direct demyelination or axon damage by production 
of reactive oxygen species, TNFs, γ-IFN, and nitric oxide.43 
Dual roles for microglia cells and macrophages have been 
proposed including destructive processes when acting as 
antigen-presenting cells and having an important function 
during neuronal recovery by scavenging damaged myelin 
following inflammatory attacks.44
Normal nerve conduction is critically dependent on proper 
functioning of sodium, potassium, and calcium ion channels. 
Animal and human data suggest alterations in distribution and 
function of sodium channels, particularly sodium subchan-
nel type Nav1.6, are present in damaged axons.45 Persistent 
sodium channel dysfunction leads to excessive intracellular 
calcium concentrations due to maladaptive Na++/Ca++ ion 
exchange. Cellular death and axonal degeneration consistent 
with chronic MS have been attributed to ion channel aberra-
tions.46 Cellular calcium levels are also regulated, in part, via 
glutamate-gated receptors. Activation of glutamate receptor 
5 can facilitate influx of extracellular calcium and release of 
additional calcium from intracellular stores.47
Estrogen supplementation in EAE animal models sug-
gests estrogens alter the immune response of MS. In vitro 
testing documents a phenotypic shift from Th1 to Th2 
expression during estrogen use in EAE models.48 The Th2-
dominant expression results from altered cytokine produc-
tion, increased IL-10 levels,49 and increased IgG1 antibody 
production specific for the autoantigen, MBP.50 Additional 
studies in estrogen receptor knockout mice have shown that 
protective effects of estradiol and estriol are dependent on 
estrogen receptor α ligands. Estrogen receptor β ligands 
may act in concert with or oppose the actions of estrogen 
receptor α.51 Estrogen receptors are expressed by dendritic52 
and microglial cells.53 Excellent reviews specific to estrogens 
effects in EAE and its potential implications for MS therapy 
are available.54,55
Traditional therapy for MS
Acute MS exacerbations are typically managed with a 
3- to 7-day course of IV methylprednisolone, which may 
be followed by a prednisone taper. Short courses of oral 
or IV corticosteroids decrease inflammation in nerve tis-
sue and shorten the duration of exacerbation. Short-course 
glucocorticoid use is generally well tolerated, but adverse 
effects may include gastrointestinal upset, mental status 
changes, and unmasking of infection. Repeated use of glu-
cocorticoids may increase the risk of fracture.1
Historically, chronic treatment for MS was aimed at 
symptoms management. Current disease-modifying therapies 
include IFN β-1a and 1b, glatiramer acetate, and natali-
zumab, which prevent relapse and slow disease   progression 
for RRMS but fail to show benefit in progressive forms 
of MS.
iFN-β/glatiramer acetate
IFN β-1a and 1b and glatiramer acetate were the first widely 
used disease-modifying agents, believed to primarily work 
by decreasing the number of T cells and interfering with 
T-cell activation. The medications have modest efficacy 
with decreases in MS relapse rates of 29%–37% and reduc-
tions in development of new, gadolinium-enhancing (GdE+) 
lesions on MRI.56–59 However, they do not reverse existing 
CNS damage and have not significantly altered development 
of permanent disability.3 Although the clinical significance 
is uncertain, efficacy of these agents may be further com-
promised by neutralizing antibodies.2,60 Excellent reviews 
of the advantages, adverse effects, and limitations of these 
therapies are published in clinical practice guidelines from 
the American Academy of Neurology61 and the European 
Federation of Neurological Societies.62
Natalizumab
Natalizumab was approved in 2004 for treatment of RRMS 
after demonstrating promising efficacy and safety results 
in Phase III trials. Natalizumab, a monoclonal antibody 
against α-4 integrin, has a novel mechanism of action of Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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blocking leukocyte trafficking across the BBB. Results from 
the AFFIRM trial demonstrated that natalizumab decreased 
relapse rates by 68% at 1 year, reduced sustained disability 
by 42% over 2 years, and decreased MRI lesion activity.63 
Natalizumab therapy is currently only available to patients 
enrolled in the Tysabri Outreach Unified Commitment to 
Health (TOUCH®) prescribing program due to its asso-
ciation with progressive multifocal leukoencephalopathy 
(PML), a rare, demyelinating neurological disorder caused 
by the reactivation of the JC virus. The incidence of PML 
in patients receiving 24–36 months of therapy is estimated 
to be 1/1000 in the United States and 2/1000 outside the 
United States. The reason for the increased risk outside 
of the United States is unknown. As of March 2010, there 
had been 67,700 natalizumab patients worldwide with 55 
confirmed cases of PML as of June 7, 2010. Approximately 
20% of patients with PML have died and the others have 
varying levels of disability.64 There are no reported cases 
of PML with ,12 infusions and no experience with natali-
zumab use beyond 36 months. Unfortunately, there appears 
to be no way to identify patients at highest risk of acquiring 
PML, and no prevention or specific treatment options for 
PML exists. Plasma exchange or immunoadsorption has 
been used in some patients with confirmed PML to lower 
circulating natalizumab levels. Many of these patients 
have experienced immune reconstitution inflammatory 
syndrome. Based on accumulating data, the FDA has now 
issued warnings that the risk of PML increases with number 
of infusions.65
Mitoxantrone
Mitoxantrone is approved for use in RRMS and SPMS but 
is considered a second-line agent due to cardiomyopathy, 
leukemia, leucopenia, and infection. Due to concerns of 
accumulating cardiomyopathy risk, maximum lifetime dose 
is 140 mg/m2, ∼11 doses.60 Patients need to have an echocar-
diogram performed at baseline and during and after treatment 
to monitor for cardiomyopathy.66
Effective therapy for slowing the course of PPMS has 
been and remains discouraging. Trials with IFN β-1a and 
1b and glatiramer have not demonstrated significant benefit. 
Preliminary data from single, small studies of mitoxantrone, 
cladribine, or methotrexate in PPMS patients have demon-
strated little to no benefit. Comprehensive data from these tri-
als are not available, and no medication has been conclusively 
proven to improve PPMS.67 Stem cell therapy has shown 
some benefit, but this therapy is still investigational and   
controversial.
New agents: major Phase III trials
Fingolimod
Fingolimod (FTY720) is a S1P1 receptor modulator. S1P1 
receptors on lymphocytes respond to various stimuli that 
signal them to egress from lymph tissue. During animal 
experiments, fingolimod use prevented the formation of 
EAE, following exposure to myelin antigens and amelio-
rated chronic neurologic deficits.68 Phase II human trials 
of fingolimod demonstrated reductions in annualized MS 
relapse rate and GdE+ lesion burden. Patients in a Phase II 
trial experienced bradycardia, elevated liver function tests, 
and macular edema, but large numbers of patients completed 
the study and many ‘placebo’ patients subsequently enrolled 
in the Phase II extension.69
Results from two Phase III trials using fingolimod have 
recently been published (Table 1). The TRANSFORMS 
Phase III study (ClinicalTrials.gov number NTC00340834) 
was a 12-month, double-blind, double-dummy study utilizing 
regimens of fingolimod 0.5 or 1.25 mg orally/day, compared 
to weekly injections of 30 µg intramuscular IFN β-1a in 1292 
RRMS patients. Enrolled patients receiving either dose of fin-
golimod experienced reductions in annualized relapse rates, 
fewer multiple relapses, and longer overall time to first relapse 
in comparison to the active control group and had a higher 
percentage of relapse-free patients. Adverse events were 
experienced by 90% of all participants; however, 87%–90% 
of the adverse events were judged to be of mild or moderate 
severity. Bradycardia (2%–10%) and first- and second-degree 
atrioventricular block (0.2%–0.7%) were more frequent in 
the fingolimod groups, commonly after the first dose. Neo-
plasms (0.5%–0.7%), lymphocytopenia (0.2%–1%), macular 
edema, and viral infections also occurred more frequently 
in fingolimod treatment patients. Two deaths occurred in the 
fingolimod 1.25-mg therapy group, one from disseminated 
primary varicella zoster infection and the other from herpes 
simplex encephalitis.70
A second 24-month Phase III trial, FREEDOMS – a 
double-blind, randomized trial, was conducted in 1272 
RRMS patients. Similar to previous trials, RRMS patients, 
ages 18–55, with EDSS scores ,5.5 were considered eli-
gible for enrollment. Oral fingolimod at 0.5 or 1.25 mg daily 
doses were compared to placebo. Both fingolimod treatment 
regimens produced similar reductions in the primary study 
endpoint annualized relapse rate and the principal secondary 
outcome measure time to disease progression. Fingolimod 
administration in this trial also postponed progression in 
EDSS scores and changes in MSFC z scores and reduced 
the number of new or enlarging T2-weighted lesions and Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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changes in brain volume. Infections, cardiovascular and 
ocular events, neoplasms, and laboratory abnormalities 
including reductions in peripheral lymphocyte counts 
and elevated liver function tests were similar to previous 
reports.71 Nearly 90% of all individuals in the Phase III trials 
completed the study, indicating a high acceptance rate for   
fingolimod.
Cladribine
Cladribine inhibits DNA synthesis by generation of 
2-chlorodeoxyadenosine triphosphate. Cladribine and its 
metabolites cause reductions in CD4+ and CD8+ cells, cytok-
ines, chemokines, and cellular migration. Results from the 
CLARITY, Phase III, trial have recently been published. 
This trial enrolled more than 1300 RRMS patients in a 1:1:1 
assignment ratio of oral cladribine 3.5 mg/kg, 5 mg/kg, or 
placebo in short-course regimens over a 96-week period. 
During the first 48 weeks of treatment, courses of oral 
cladribine or placebo were given for the first 4–5 days of 
a 28-day period. In the 3.5 mg/kg group, two courses of 
cladribine were followed by two courses of placebo, starting 
on day 1 and followed at weeks 5, 9, and 13. For enrollees 
in the remaining two groups, cladribine 5 mg/kg or placebo 
was given for four courses, starting on day 1 and followed 
at weeks 5, 9, and 13. During the second 48-week treatment 
block, placebo and both cladribine-assigned patients received 
two courses of their assigned medications, starting weeks 48 
and 52, 8–10 days total treatment. Subcutaneous injections 
of IFN β-1a 44 µg three times weekly as rescue therapy was 
allowed after 24 weeks if patients had sustained disability or 
more than a single relapse.
Patients in either cladribine group had significantly fewer 
relapses, and significantly higher percentages remained 
‘relapse-free’ in comparison to those assigned placebo. 
Reductions in need for rescue medication and prolonged 
time to first relapse also occurred in cladribine groups. 
Lymphocytopenia, neutropenia, and thrombocytopenia were 
more common in patients receiving cladribine. Cladribine-
treated patients experienced more mild or moderate infections 
including herpes zoster infections, and one death occurred 
due to reactivation of tuberculosis.72
Rituximab
PPMS patients receiving rituximab during the OLYMPUS 
trial, the only Phase III trial, did not experience significant 
benefit in time to confirmed disease progression over the 
96-week study period. However, rituximab patients did dem-
onstrate significant benefit with less mean T2 volume change 
from baseline compared to placebo. Subgroup analysis from 
the OLYMPUS trial suggests that confirmed disease progres-
sion was delayed in rituximab-treated patients ,51 years old 
and those with GdE+ lesions (see Figure 4).73
Major Phase II trials
Laquinimod
Laquinimod is another novel oral agent that causes an 
immune response shift from Th1 to Th2. Roquinimex 
(linomide), which is structurally similar to laquinimod, 
was found to cause pericarditis, myocardial infarction, and 
serositis during Phase III trials, so further research was 
suspended. Results from a 24-week laquinimod Phase II 
trial enrolling 306 patients, 18–50 years old, with RRMS 
have recently been reported (Table 2).75 Laquinimod doses 
of 0.6 or 0.3 mg daily were compared to placebo. Reduction 
in the number of GdE+ lesions on MRI was the primary 
endpoint, and secondary endpoints included the cumulative 
number of GdE+ and T2-weighted lesions and number of 
clinical relapses.
At the end of the 24-week study period, the adjusted mean 
cumulative number of GdE+ lesions per scan, T2-weighted 
lesions, and cumulative number of new T1-hypointense 
lesions from the last four assessment points were all signifi-
cantly fewer in the laquinimod 0.6 mg/day treatment group, 
compared to placebo. No significant change in EDSS scores 
was observed, but the relatively short study period may have 
influenced this finding. In contrast, the 0.3 mg/day laquini-
mod dose did not demonstrate significant benefits in the 
primary or secondary study endpoints. The overall incidence 
of adverse events, experienced by 77%–84.7% of all partici-
pants, was similar across all groups. Serious adverse events 
for individuals on laquinimod during this trial consisted of 
severe menometrorrhagia with myofibroma, elevation of liver 
enzymes without concomitant jaundice, and exacerbation of 
pre-existing glaucoma.
Alemtuzumab
Alemtuzumab (Campath-1H®) (Campath®; Genzyme 
Corporation, Cambridge, MA, USA) is a humanized mono-
clonal antibody that targets CD52, a highly expressed protein 
on monocytes and lymphocytes. Early human studies of 
alemtuzumab given in a pulsed regimen led to significant 
and persistent T-cell reductions and shifted the lymphocyte 
profile.77 A 36-month randomized, blinded Phase II trial 
of alemtuzumab versus IFN β-1a in therapy naive, early 
RRMS patients was recently completed. Patients with EDSS 
scores of 3 or less and with onset of symptoms within the Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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previous 36 months at time of screening were allocated to 
alemtuzumab 12 or 24 mg/day or IFN β-1a 44 µg given 
subcutaneously three times per week. Alemtuzumab admin-
istration regimens consisted of 5-consecutive-day cycles 
of intravenous infusions during the first month followed 
by three consecutive daily intravenous infusions given at 
months 12 and 24. Primary outcome measures were fre-
quency of relapse rates and time to sustained accumulated 
disability. Secondary outcome measures included changes 
in T2-weighted MRI findings, brain volume, and proportion 
of patients without relapse.
Patients receiving either dose of alemtuzumab demon-
strated significantly less sustained accumulated disability 
at 6 months and fewer relapses than did patients receiving 
IFN β-1a. Both alemtuzumab dosing regimens produced 
significant benefits with respect to comparator for early 
MRI lesion changes and brain volume. The safety profile 
of alemtuzumab was markedly different from IFN β-1a, 
with alemtuzumab-administered patients more likely to 
experience elevations in liver function tests, upper and 
lower   respiratory tract   infections, hyper or hypothyroidism, 
stomatitis, and rash. Five of six cases of immune thrombo-
cytopenic purpura occurred in the alemtuzumab groups, 
causing the death of one patient, and ultimately leading to 
suspension of the trial.77
Daclizumab
Daclizumab is a monoclonal anti-CD25 antibody that stimu-
lates the production and enhances the function of CD56bright 
natural killer cells. A recent study was conducted to deter-
mine whether combination daclizumab and IFN β-1a or 1b 
therapy would produce favorable additive effects on relapse 
rate, lesion development, and progression. Additional out-
come measures included investigation of new biomarkers 
and exploration of different dosing regimens.79 Fifteen MS 
patients who had experienced more than one exacerbation 
or had increasing disability within the previous year and at 
least two contrast-enhancing lesions on MRI were enrolled. 
Intravenous infusions of daclizumab doses of 1 mg/kg were 
given at 2-week intervals for the first two doses followed 
thereafter by infusions every 4 weeks. If MRI determined 
that contrast-enhancing lesions were reduced by 75% over 
Lymph node
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Figure 4 New MS drug mechanisms of action. Schematic depiction of putative targets for the new MS treatment modalities. in lymphoid organs in the periphery, autoreactive 
T cells interact with APC and B cells and, after activation, are able to cross the BBB. in the CNS, reactivation of autoreactive T cells results in production of effector cytokines 
such as iFN-γ, TNF-α, and iL-17, attraction of macrophages and microglia, antibody production by plasma cells, and attack by CD8+ T cells. in concert, these mechanisms 
lead to demyelination and axonal injury. interactions of immune cells are shown with black arrows and transmigration over the BBB is displayed with yellow arrows. Red 
arrows indicate therapeutic interactions with pointed arrows standing for targeting of specific cell types or molecules, T-shaped lines in red indicate blocking of pathways or 
receptors. Hypothetic mechanisms not proven in vivo are depicted with a question mark.
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baseline at the 5.5-month assessment, β-IFN was tapered 
over 2–4 weeks, discontinued, and daclizumab monotherapy 
was continued for 10 months. If patients did not reach a 
75% reduction in contrast-enhanced lesions at the 5.5-
month assessment, the dose of daclizumab was doubled. 
IFN β-1a or 1b therapy was reinstated if a patient’s monthly 
MRI revealed sustained lesion progression in any 2-month 
period. The number of T2-weighted lesions, brain fractional 
volume, volume of T1-weighted lesion hypointensities, and 
changes in EDSS, Scripps Neurological Rating Scale, and 
MSFC scores were secondary outcome measures. Blood 
samples were analyzed to quantify the number and percentage 
changes in CD4+/CD3+, CD8+/CD3+ T cells, and CD56bright/
CD3− and CD56dim/CD3− natural killer cells. IFN β was 
discontinued in 14 patients but was reinstated later in three   
patients.
Overall, new contrast-enhancing lesions were reduced by 
72%, and improvements were reported for all of the clinical 
assessments. Seven patients were characterized as partial 
responders and seven fulfilled criteria as full responders 
based upon percentage decrease in CD8+/CD4+ cells. Two 
patients developed systemic immune response reactions and 
did not complete the trial. Lymphopenia and generalized 
lymphadenopathy occurred in two other patients requiring 
interruption of daclizumab therapy but not withdrawal from 
the trial.79
Rituximab
Rituximab is a chimeric monocolonal antibody targeting 
CD20+ B lymphocytes, which has been used for B-cell 
  lymphomas as adjuvant chemotherapy. Although T-cell 
infiltration and response have long been linked to disease 
activity in MS, autoimmune B cells and the corresponding 
humoral response also play a role in disease progression.
Rituximab was studied in a Phase II, double-blind, 
placebo-controlled trial enrolling 104 patients with RRMS.78 
During the 48-week study, patients were stratified in a 2:1 
fashion to receive rituximab 1000 mg intravenously or 
placebo on weeks 1 and 15 and were monitored for disease 
progression based on relapse rates and lesions detected 
with MRI. Patients enrolled were 18–55 years old, had at 
least one relapse in the previous year, and had baseline 
EDSS scores ranging from 0 to 5.0. Patients were excluded 
if the relapse occurred in the previous 30 days or if they 
required recent use of anti-inflammatory therapy or alterna-
tive MS treatments. Patients’ EDSS scores, MRI imaging 
changes, peripheral B-cell levels, and adverse events were 
followed.
Patients treated with rituximab had significantly fewer 
total and new GdE+ lesions at weeks 12, 16, 20, and 24 of 
the trial (P , 0.001); these results were sustained for 48 
weeks (P , 0.001). Additionally, the proportion of patients 
who experienced a relapse was significantly lower in the 
rituximab group at weeks 24 (14.5% versus 34.3%, P = 0.02) 
and 48 (20.3% versus 40.0%, P = 0.04). Adverse events were 
higher in the rituximab group, with infusion-related adverse 
events within 24 h being the most common (78.3% versus 
40.0%). Urinary tract and sinus infections were also more 
common, although no clinically significant opportunistic 
infections were reported. Within the treatment group, 16 of 
65 patients (24.6%) tested positive for antichimeric antibod-
ies to rituximab.78
Fumarate
Dimethyl fumarate and its active metabolite, methyl hydro-
gen fumarate, have been shown to decrease oxidative stress 
and protect axons from inflammatory mediators.76 Fumarate 
was studied in 257 patients in a double-blind, prospective, 
randomized, placebo-controlled trial, where patients received 
oral fumarate 120 mg once daily, 120 or 240 mg three times 
daily, or placebo. The trial was of 24 weeks’ duration followed 
by a 24-week extension phase. The placebo group during the 
initial 24-week study was switched to the fumarate 240 mg 
three times daily dose during the 24-week extension to aug-
ment safety analysis.
Study results demonstrated a decrease in the primary 
endpoint of mean number of GdE+ lesions by 69% in the 
240 mg three times daily treatment group versus placebo from 
week 12 to 24 (4.5 versus 1.4, P , 0.0001). Fumarate 240 mg 
three times daily reduced new or enlarging T2-hyperintense 
(P = 0.0006) and T1-hypointense (P = 0.014) lesions and 
relapse rates by 32% (0.44 versus 0.65 for placebo; P = 0.272) 
compared to placebo. Adverse events that were higher in all 
fumarate groups included flushing, abdominal pain, head-
ache, and fatigue.76
Teriflunomide
Teriflunomide, an active metabolite of leflunomide, inhibits 
dihydro-orotate dehydrogenase, a key enzymatic step required 
in pyrimidine synthesis. Teriflunomide inhibits T-cell activa-
tion by blocking interaction with antigen-presenting cells, 
inhibiting tyrosine kinase, or other inflammatory mediators.80 
A 36-week, double-blind, Phase II study enrolling both 
RRMS and SPMS patients evaluated the effectiveness of 
teriflunomide 7 or 14 mg daily versus placebo. The number 
of combined unique MRI lesions per scan was the primary Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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study endpoint, whereas relapse rate frequency, accumulation 
of disability, and MRI-defined disease burden represented 
the major secondary endpoints.
Significant reductions in combined unique active lesions 
per scan occurred in both the teriflunomide 7 (P , 0.03) 
and 14 mg (P , 0.01) groups compared to placebo.74 The 
TEMSO trial, 108-week, placebo-controlled Phase III study 
using active treatment regimens of teriflunomide 7 or 14 mg/
day, has completed recruitment but is awaiting completion 
(www.clinicaltrials.gov).
estrogen
Retrospective human cohort studies81 and a prospective trial82 
tracking relapse rates in women with RRMS have found 
that relapses are less common during the third trimester of 
pregnancy and more exacerbations occur during the first 
3 months postpartum.81,82
Although women with more frequent relapses prior to 
and during pregnancy have a higher likelihood of relapses in 
the 3-month postpartum period, no pattern exists to predict 
in advance who is more likely to relapse. After the initial 
3-month postpartum period, relapse rates tend to regress to 
prepregnancy frequencies for the next 21 months without 
affecting disease progression.82
Two studies have been published that evaluated 
estrogen supplementation in nonpregnant women with 
MS. Sicotte et al83 enrolled 12 female patients with clinically 
definite MS; six with RRMS and six with SPMS. Ten patients 
(six RRMS, four SPMS) finished the 18-month crossover 
design trial, which consisted of 6 months’ treatment with oral 
estriol (8 mg/day) preceded and followed by ‘usual’ therapy. 
Major study endpoints included EDSS, PASAT, nine-hole 
peg test, MRI scans, and response to delayed hypersensi-
tivity testing to tetanus and candida. Serum estriol levels 
obtained during the treatment phase of the study indicated 
estriol levels were comparable to women who were 6 months   
pregnant.
GdE+ lesion volume and number were reduced in 
all 10 patients at the end of the treatment phase when com-
pared to pretreatment baselines; reductions were primarily 
driven by the changes in the six RRMS patients. Lesion 
numbers and size returned to near pretreatment levels after 
the 6-month post-treatment block.
During a subsequent 4-month retreatment extension 
phase, MRI lesion volumes and numbers again signifi-
cantly decreased. PASAT scores among RRMS patients 
improved, but no other clinical measures improved or 
reached statistical significance for either RRMS or SPMS 
patients. Reduction in delayed hypersensitivity reaction to 
tetanus and candida, which are surrogate markers for Th2 
immunity shifting, was evident during the treatment phase. 
Estriol supplementation was generally well tolerated with 
menstrual cycle abnormalities being the most frequently 
associated symptom. During the 4-month retreatment 
extension phase, all but one patient also received proges-
terone 100 mg/day.83
A second estriol trial enrolled 10 female patients (six 
RRMS and four SPMS) in a crossover design trial in similar 
6-month blocks to determine the mechanisms responsible for 
the Th2 shift observed in the earlier study. MRI scans were 
obtained monthly, and blood was obtained every 3 months. 
Immune cell and cytokine population analysis was conducted 
to elucidate estriol effects.
Decreases in CD4+ and CD8+ T cells, increases in CD19+ B 
cells, and no change in CD 64+ monocytes/macrophages were 
noted during the estriol treatment phase with a greater effect 
experienced by the RRMS patients. Increased intracellular 
IL-5 and IL-10 and decreased intracellular TNF-α occurred 
during estriol treatment. Reductions of cells to pretreatment 
levels occurred during the post-treatment phase.84
Stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) potential for 
modulating or reversing defective immunological responses 
of MS is perhaps the most hopeful of all emerging therapies, 
at least in theory. The premise is that unaffected stem cells 
can be used to ‘reset’ or restore self-tolerant cellular popula-
tions of the immune system after the dysfunctional cells have 
been eliminated via irradiation or chemotherapy.
The origin of the stem cells is either autologous (from the 
same individual) or allogenic (cells from another individual 
without the disease in question). Nonmyeloablative therapy 
is commonly employed for autologous HSCT which does not 
completely obliterate marrow cells but significantly reduces 
the number of cells. The patient’s remaining stem cells are 
capable of self-regeneration, although sometimes after che-
motherapy, autologous stem cells are supplemented to lessen 
the patient’s duration of marrow suppression. In allogenic 
HSCT, myeloablative chemotherapy is used to completely 
destroy the patient’s marrow, thus theoretically eliminating 
the defective cells entirely. The intensity of myeloablative 
response is determined by the specific agent chosen, whether 
combinations of ablative agents are used, and if chemotherapy 
is supplemented with irradiation. When allogenic cells are 
used for replacement, ‘host-versus-graft’ reactions post stem 
cell transfer are possible.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Autologous HSCT is not generally considered a ‘cure’ 
because small numbers of ‘defective’ cells may re-emerge. 
Some argue that autologous HSCT is more appropriate for 
individuals with nonlife-threatening autoimmune diseases 
because of mortality risk associated with allogenic HSCT.85 
Allogenic HSCT is typically reserved for patients with severe 
or rapidly progressive disease since the risks associated with 
this procedure are more substantial than autologous HSCT.
After successful ‘proof of concept’ testing in EAE ani-
mal models, HCST underwent human Phase I and Phase II 
trials, mostly in refractory MS patients.86 Early MS trials 
typically enrolled PPMS or SPMS patients and used high-
intensity myeloablative regimens, which often also included 
irradiation or busulfan. These trials generally arrested dis-
ease progression in 30%–70% of patients, depending upon 
baseline EDSS scores and duration of post-treatment follow-
up.87,88 These favorable findings were offset by substantial 
mortality (4%–40%) and an engraftment syndrome char-
acterized by rash and noninfectious fever in up to 50% of   
patients.87–89
Table 3 Ongoing Phase iii trials
Experimental  
agent
Intervention Description Trial identifiera Status/ 
completion date
Anticipated  
no. of patients
Teriflunomide Teriflunomide 7 or  
14 mg versus placebo
Determine the effect of 
teriflunomide on  
conversion of CiS to  
clinically definite MS
NCT00622700  
TOPiC
Recruiting/ 
April 2015
780
Teriflunomide 7 or  
14 mg versus iNF β-1a
effectiveness of  
teriflunomide versus  
iNF β-1a in RRMS
NCT00883337  
TeNeRe
Recruiting/ 
October 2011
300
Teriflunomide versus  
placebo
effectiveness and safety of 
teriflunomide versus  
placebo for RRMS
NCT00134563  
TeMSO
Ongoing/ 
July 2010
1080
Teriflunomide 7 or  
14 mg versus placebo
Effect of teriflunomide  
versus placebo for RRMS
NCT00751881  
TOweR
Recruiting/ 
September 2011
1110
Teriflunomide 7 or  
14 mg
Safety extension study NCT00803049 Ongoing/ 
October 2010
1080
Laquinimod Laquinimod 0.6 mg  
PO daily versus  
placebo
Safety and efficacy of 
laquinimod versus placebo  
in RRMS
NCT00509145  
ALLeGRO
Ongoing/ 
December 2010
1000
Laquinimod 0.6 mg  
PO daily versus placebo, 
with iNF β-1a as active 
comparator
Efficacy, safety, and  
tolerability of laquinimod 
versus placebo for RRMS
NCT00605215  
BRAvO
Ongoing/ 
June 2011
1200
Fumarate Fumarate 240 mg BiD,  
250 mg TiD,  
versus placebo
Efficacy and safety of  
fumarate in RRMS
NCT00420212  
DeFiNe
Ongoing/ 
December 2010
1011
Fumarate 240 mg BiD  
or TiD versus placebo  
with GA as an active 
comparator
Safety and efficacy of  
fumarate in RRMS
NCT00451451  
CONFiRM
Ongoing/ 
April 2011
1232
Alemtuzumab Alemtuzumab 12 or  
24 mg versus iNF β-1a
Safety and efficacy of 
alemtuzumab in RRMS  
who relapse while on GA  
or iNF β
NCT00548405  
CARe-MS ii
Ongoing/ 
September 2011
840
Alemtuzumab 12 mg  
versus GA
Safety and efficacy of 
alemtuzumab in RRMS  
who have not previously  
been treated except with 
steroids
NCT00530348  
CARe-MS i
Ongoing/ 
May 2011
581
Daclizumab Daclizumab high-yield  
process 150 mg versus 
NF β-1a
Determine superiority of 
DAC HYP compared to  
iNF β-1a in RRMS
NCT01064401 Not yet open/ 
November 2013
1500
Note: Data used to construct table obtained from ClinicalTrials.gov. Accessed June 22, 2010.
Abbreviations: CiS, clinically isolated syndrome; MS, multiple sclerosis; iNF, interferon; RRMS, relapsing-remitting multiple sclerosis; GA, glatiramer acetate; DAC HYP, 
daclizumab high yield process.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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More recent trials have enrolled less severely affected MS 
patients and have used less intense myeloablative regimens. 
These trials maintained the impressive benefits associated 
with HSCT such as increased survival and improved disability 
status ratings while minimizing but not totally eliminating the 
risk of mortality.90–94 Burt et al have completed an excellent 
review of HSCT use in nonmalignant diseases.85
Due to the successes of these Phase II trials, patients are 
currently being recruited for ongoing HSCT Phase III trials 
(Table 3).
Table 4 Steroid-based combination trials
Study Study  
subjects
N Regimen Time of 
evaluation
Annualized 
relapse rate 
(95% confidence 
interval)a
Mean  
cumulative  
number of  
new (T2) lesions
Comments
MeCOMBiN 
Study96
RRMS 169  
172
iNF β-1a 30 µg  
iM once weekly +  
placebo  
iNF β-1a 30 µg  
iM once weekly +  
methylprednisolone  
500 mg/day PO for 3 days
3 years 0.26  
0.15  
Relative  
reduction: 42%  
P = 0.086  
Patients adherent  
to regimen to  
end of study
8.0  
5.2  
Relative reduction: 35%  
P = 0.007
Sustained disability 
for 6 months:  
44  
46  
Hazard ratio: 0.879  
(95% Ci 0.566–1.365)   
P = 0.57
NORMiMS95 RRMS 64  
66
iNF β-1a (44 µg SC.  
three times weekly) +  
placebo iNF β-1a  
(44 µg SC.  
three times weekly) + 
methylprednisolone  
200 mg 5 consecutive days  
every 4 weeks
96 weeks 0.59  
0.22  
Relative  
reduction: 62%  
(95% Ci: 39–71)  
P , 0.0001
(n = 56) 3.5  
(95% Ci: 2.7–4.7)  
(n = 54) 2.7 
(95% Ci: 2.0–3.8)  
Relative reduction: 23%  
(95% Ci:  
0.50–1.19)  
P = 0.24
High withdrawal 
rate. Significant 
reduction in 
relapse rate needs 
confirmation from 
additional studies
ACT97 RRMS 78  
83  
74  
78
i iNF β-1a 30 µg  
iM once weekly +  
Placebo  
iNF β-1a 30 µg  
iM once weekly +  
20 mg MTX PO weekly  
iNF β-1a 30 µg  
iM once weekly +  
1000 mg ivMP/day ×  
3 days bimonthly  
iNF β-1a 30 µg iM once 
weekly + 20 mg  
MTX weekly + 1000 mg 
ivMP/day × 3 days  
bimonthly
52 weeks 0.53a 
0.40a  
0.40a  
0.28a
1.8  
1.9  
1.5  
0.9  
MTX: odds ratio 0.98  
(95% Ci = 0.63–1.54) 
wald P value = 0.93  
ivMP: odds ratio 0.74 
(95% Ci = 0.47–1.15) 
wald P value = 0.18
event rates were 
lower in ACT than 
other trials reducing 
power of study to 
detect differences 
MRi measures highly 
skewed rank-based 
statistics chosen for 
most endpoints
ASA98 RRMS 60  
58  
63
iNF β-1a 30 µg  
iM once weekly +  
AZA and steroid  
placebos  
iNF β-1a 30 µg  
iM once weekly +  
AZA 50 mg/day  
orally + steroid  
placebo iNF β-1a 30 µg  
iM once weekly +  
AZA 50 mg/day orally + 
prednisone 10 mg/day  
every other day
initial  
analysis:  
2 year
0.73  
0.91  
1.05  
2-year adjustedb 
annualized  
relapse rate  
Trend between 
group 1 and 3  
(P = 0.60)
30.3% (P , 0.05)  
24.6%  
14.5%  
Median percent change 
T2 lesion volume from 
baseline MRi at 2 years. 
No difference observed  
at 5 years
No superiority 
of combination 
therapy for primary 
endpoint-relapse 
rate  
At 5 years, 
no statistically 
significant 
differences in 
sustained disability 
progression
Notes: aAdjudicated relapses within 1-year follow-up, based on all patients; bAdjusted for baseline relapse rate, eDSS, duration of MS, age, and gender.
Abbreviations: RRMS, relapsing remitting multiple sclerosis; iNF, interferon; AZA, azathioprine; MTX, methotrexate, ivMP, intravenous methylprednisolone.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Combination therapy
While first-line medications such as the β-IFNs and glati-
ramer acetate can reduce relapse rates and retard disease 
progression in some individuals, most patients progress 
to further disability. The complex immunological cascade 
in MS involving T and B cells, multiple adhesion ligands, 
and numerous secondary costimulatory molecules suggests 
that multiple points of intervention would be plausible. 
Using medications with differing mechanisms of action 
might produce additive or synergistic efficacy when used 
in combination. Moreover, combination therapy for other 
inflammatory and autoimmune disorders such as rheumatoid 
arthritis is commonplace. Trials to determine the safety and 
efficacy of combination therapy for MS patients have become 
an area of more intensive research.
Steroid-based combination trials
Combination use of IFN β-1a with steroids in the NORMIMS95 
and MECOMBIN96 trials led to reductions in relapse rates 
but did not affect time to sustained progression (Table 4).96 
Data generated from the NORMIMS trial may have been 
influenced by small enrollment numbers and a high dropout 
rate exceeding 50%. Patients assigned to steroid groups in 
the NORMIMS and MECOMBIN studies experienced a 
higher percentage of adverse effects. IFN β therapy com-
bined with methotrexate, methotrexate and steroids, low-dose 
azathioprine, and low-dose azathioprine plus steroids has not 
resulted in significant reductions of relapse rates.97,98
Natalizumab combination trials
Relapse rate reductions and significantly fewer new or 
expanding lesions detected by MRI have been documented 
in trials combining IFN β-1a IM or glatiramer acetate with 
natalizumab (Table 5). The combination of natalizumab 
and glatiramer did not cause significantly more frequent or 
severe adverse effects. However, the combination group did 
produce more neutralizing antibodies. It appeared that the 
presence of persistent antibodies might be related to increased 
relapse rates or particular infusion reactions. No evidence of 
PML was reported during the GLANCE trial or its extension 
phase.99 However, the SENTINEL trial in which natalizumab 
was combined with IFN was halted early due to the detection 
of PML in two individuals.33
Other smaller investigations combining therapies includ-
ing cyclophosphamide with IFN β100 or using mitoxantrone 
with either IFN β101 or glatiramer acetate102 have shown 
promise. Numerous other Phase II studies using IFN β or 
glatiramer acetate combined with sodium-blocking agents, Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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statins, antibiotics, or immunostimulants are currently 
underway. Conway et al have recently published an excel-
lent review.103
New developments in treatment  
of the symptoms of MS
MS patients suffer from a variety of symptoms which 
may be treated with pharmacotherapy (Table 6).104 Other 
health interventions including a good diet and exercise may 
minimize symptoms and help avoid drug therapy. Nondrug 
interventions such as intermittent self-catheterization for 
urinary postvoid residual and surgical procedures such as 
tendon release for spasticity also are utilized. Consultation 
services such as those in neuropsychology, otolaryngology, 
and physical therapy are commonly needed to optimize 
symptom management.
Almost all medications used to manage the symptoms of 
MS are not specifically indicated for or approved for use in 
MS patients. Lists of medications used for the given symp-
toms of MS include both older and newer drugs that share 
similar mechanisms of action; a discussion of the specific 
agents is beyond the scope of this article. However, a few 
developments in the pharmacotherapy of MS symptoms 
have occurred, most notably dalfampridine (formally called 
fampridine-SR and 4-aminopyridine), which was recently 
approved for specific use in MS patients to improve walk-
ing. In a large survey, it was found that walking difficulties 
affect nearly two-thirds of MS patients, with 70% of those 
patients reporting it as the most challenging aspect of their 
disease. Fatigue, which contributes to mobility, also was 
very common, affecting 76% of MS patients at least twice 
weekly.104,105
Dalfampridine (Ampyra™; Acorda Therapeutics, Inc., 
Hawthorne, NY, USA) is a lipid-soluble drug that readily 
crosses the BBB and blocks both peripheral and CNS potas-
sium channels. The exposure of potassium channels as a 
result of myelin destruction in MS allows for disruption 
of the generation and conduction of action potentials.107 
Dalfampridine has been found to have a dose-dependent 
effect to block slowly inactivating or noninactivating 
voltage-dependent potassium channels.108 It has been sug-
gested that this relatively specific mechanism of action 
could explain why only certain patients respond well to the   
drug.109
The effects of dalfampridine on various measures of 
clinical efficacy in MS, such as the EDSS, MSFC, nine-
hole peg test, Timed 25-Foot Walk Test (T25 WT), 12-Item 
Multiple Sclerosis Walking Scale (MSWS-12), and Lower 
Extremity Manual Muscle Testing (LEMMT), were evaluated 
in early studies. From those studies, measures reflective of 
walking speed (T25 WT and MSWS-12) and lower extrem-
ity muscle strength (LEMMT) emerged as outcomes most 
closely associated with the clinical efficacy of the drug. 
Investigation of the safety of dalfampridine established the 
recommended dosage of a sustained-release 10-mg tablet to 
be taken orally twice daily. In a Phase II study of 206 patients 
randomized to twice daily dosing with dalfampridine-SR 
10, 15, 20 mg, or placebo, serious adverse effects occurred 
at similar rates in the dalfampridine-SR 10 mg and placebo 
groups (17% and 15%) while higher rates were found in the 
dalfampridine-SR 15- and 20-mg groups (24% and 30%). 
Seizures occurred in two patients in the 20-mg group, 
  corroborating other data of this serious adverse effect associ-
ated with the drug.110,111
The approval of dalfampridine was primarily based 
on two Phase III randomized, double-blind, multicenter 
clinical trials of patients with all types of MS. Goodman 
et al randomized 301 patients in a 3:1 ratio to 14 weeks 
Table 6 Pharmacotherapy of common MS symptoms104–106
Symptom Prevalence estimate (%) Pharmacotherapies used
Fatigue 75–90 Amantadine, amphetamines, antidepressants, methylphenidate, modafinil, pemoline
Weakness/walking difficulties 65–70 Dalfampridine
Spasticity 75–90 Baclofen, botulinum toxin, clonazepam, dantrolene, diazepam, gabapentin, 
pregabalin, tizanidine
Pain/dysesthesias 50–60 Amitriptyline, carbamazepine, gabapentin, lamotrigine, phenytoin, topiramate
Bladder dysfunction 60–75 Amitriptyline, botulinum toxin, darifenacin, desmopressin, dicyclomine, 
hyoscyamine, imipramine, oxybutynin, propantheline, prazosin, solifenacine, 
tolterodine, trospium
Depression 25–50 Antidepressants
Cognitive deficit 50–60 Amphetamines, donepezil, memantine, rivastigmine
Sexual dysfunction 50–65 Alprostadil, sildenafil, tadalafil, vardenafil
Tremor/ataxia 30–60 Buspirone, clonazepam, isoniazid, primidone, propranololDrug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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of dalfampridine-SR 10 mg twice daily or placebo in the 
MS-F203 trial; patients were allowed to continue stable 
doses of MS medications including immunosuppressants. 
The primary endpoint was the T25FW, with response 
defined as improvement for at least three of four visits 
  during the treatment period. The MSWS-12 was used to 
assess patients’ evaluations of the clinical meaningfulness of 
the T25 WT results. Results showed a significantly greater 
number of patients in the dalfampridine (34.8%) compared 
with placebo group (8.3%) achieved the primary T25 WT 
outcome (P , 0.0001), with a 25.2% compared to 4.7% 
improvement in walking speed in the dalfampridine group. 
Greater improvement, which was statistically significant 
(P = 0.0002), was seen in the MSWS-12 scores in the 
T25 WT responders (−6.84) compared to nonresponders 
(0.05). Overall adverse events occurred with a similar 
  frequency in dalfampridine and placebo groups. Eleven 
patients (4.8%) in the active drug group withdrew due to 
adverse events, although three patients withdrew during a 
2-week placebo run-in period before receiving dalfampri-
dine. Two serious events in the dalfampridine group were 
believed to be related to treatment, including a seizure judged 
as possibly related which occurred in a patient who suffered 
from concurrent sepsis.110
The second Phase III trial (MS-F204) included simi-
lar MS patients with some degree of walking impairment 
from 39 centers in the United States and Canada. Patients 
were randomized 1:1 to dalfampridine-SR 10 mg twice 
daily or placebo for 8 weeks. The proportion of patients 
who   experienced an improvement in the primary outcome 
T25 WT and classified as responders was significantly 
greater in the dalfampridine (42.9%) compared to placebo 
(9.3%) group (P , 0.001); response occurred in all types 
of MS patients. Secondary outcomes also favored dalfam-
pridine responders, with an average increase in mobility 
over the treatment period (24.7% compared to 7.7%) and a 
significant increase in leg strength compared to the placebo 
group (P = 0.028). Dalfampridine responders also demon-
strated improved self-rated MSWS-12 scores compared to 
nonresponders. Adverse effects in the dalfampridine group 
affecting more than 10% of patients included urinary tract 
infections, falls, and insomnia, but headache, asthenia, 
dizziness, nausea, back pain, balance disorder, and par-
esthesia all occurred at least twice as commonly as in the 
placebo group. Only one patient in the active drug treatment 
group was discontinued due to a serious adverse effect, 
which was a patellar fracture judged not to be treatment   
related.112
Follow-up information from the two Phase III trials also 
has been positive. The dalfampridine responders group in the 
MS-F204 trial was found to have significant improvement 
in the physician-reported Ashworth score for spasticity.113 
Extended efficacy and safety data from 269 patients from 
the MS-F203 trial enrolled in an open-label study showed 
that 187 patients (69.7%) were still enrolled after an aver-
age drug exposure of 2.1 years; the discontinuation rate due 
to adverse events was 10.8%. Efficacy analysis indicated 
66 of 269 patients (24.9%) could be classified as Extension 
Time Walk Responders (ETWRs) after 1 year of treatment; 
those patients had a mean improvement in walking speed 
of .30% at 1 year and 22% at 2 years, compared to base-
line. Among patients previously defined as T25 WT in the 
original trial, 42.9% met criteria for Extension Time Walk 
Responders. Safety analysis revealed four seizure-related 
events, giving an incidence of 0.41/100 dalfampridine 
patient-years, compared to 0.35 previously reported in the 
general MS population.114 Finally, data from open-label 
analysis of patients from both Phase III trials showed that 
dalfampridine responders continued to show improvement 
in walking speed after 2.5 years; a pooled analysis of 631 
patients including the Phase III patients plus those from a 
Phase II study demonstrated that 37.3% of active drug com-
pared to 8.9% of placebo recipients were T25 WT responders, 
with an average improvement in walking speed of 25.3%. 
Response to dalfampridine was independent of patient factors 
such as gender, age, baseline EDSS score, MS type, disease 
duration, and treatment with the various immunomodulator   
drugs.115
Data are lacking to help identify which patients will 
respond favorably, or poorly, to dalfampridine. Earlier 
data from a study using dalfampridine-SR 17.5 mg twice 
daily suggested a correlation between dalfampridine serum 
concentrations greater than 60 ng/mL and clinical efficacy.116 
In contrast, mean plasma dalfampridine concentrations of 
27.6–29.2 ng/mL with a range of 0–66.8 ng/mL were reported 
in one of the Phase III trials, suggesting few patients achieved 
a concentration above 60 ng/mL at the recommended 10 mg 
twice daily dosage.110 In addition, it is not yet fully delineated 
what, if any, risk of seizures is associated with dalfampridine 
at the recommended dosage and what patients may be at 
increased risk, although the drug is labeled as contraindi-
cated in patients with a history of seizures or/and those with 
renal impairment. (The drug is 85% renally eliminated.)109 
Nerispirdine, another potassium-channel blocker similar to 
dalfampridine, is currently being studied in Phase II trials.117 
However, nerispirdine also blocks voltage-dependent sodium Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
362
Barten et al
channels, which may minimize or eliminate any risk of seizure   
activity.118
Other developments in the treatment of MS symptoms 
concern additional insight to the use of existing agents. 
Fatigue is the single most common symptom of MS, and 
modafinil is frequently utilized for this disabling symptom.104 
A recent double-blind study by Lange et al in a small number 
of MS patients (n = 21) demonstrated that modafinil titrated 
to 200 mg once daily for 8 weeks provided a sustained 
improvement in fatigue, as measured by the Fatigue Severity 
Scale, when compared to placebo. Modafinil resulted in a 
significant lowering of the mean Fatigue Severity Scale score 
from a baseline 57.0 to 44, compared to a change from 52 
to 52.5 in the placebo group (P = 0.035).119 Results from the 
study consistently corroborated positive data with modafinil 
from open-label studies, but contrasted with those from the 
only previously reported double-blind, placebo-controlled 
trial which failed to demonstrate benefit from modafinil 
over a 5-week treatment period.120 Stankoff et al had found 
that modafinil typically titrated to at least 300 mg daily 
did provide benefit as measured by the Modified Fatigue 
Severity Scale, but that similar benefit also occurred in 
the placebo group.121 Because the most prolonged study 
of modafinil in MS patients has only been 12 weeks, there 
is a need for long-term data regarding the value of this   
agent.
The symptom of spasticity in MS patients can be useful for 
movement, but often causes pain, discomfort, or debilitation, 
which requires pharmacologic intervention. Baclofen and 
tizanidine are effective oral agents but commonly cause 
adverse effects of somnolence, weakness, or fatigue. The use 
of tizanidine at bedtime may provide benefit with less adverse 
effects compared to daytime use, but multiple daily dosing 
is often required.106 Intrathecal baclofen offers an effective 
alternative to oral agents, but requires pump implantation 
and management. Botulinum toxin injectable was approved 
in 2010 in the United States for treatment of spasticity of 
the upper limbs, but its value is limited by its focal effect 
on individual muscles in MS patients, who often have 
spasticity affecting an entire limb.122 Finally, cannabinoids 
have been investigated for spasticity in MS patients. Most 
studies have utilized Cannabis sativa extract or the active 
constituent ∆9-tetrahydrocannabinol given as oral or oromu-
cosal spray preparations and several well-designed blinded 
placebo-controlled trials have been conducted. Globally, 
cannabinoids have been found to have consistent subjective, 
patient-reported benefits on spasticity. However, benefit 
has typically not been seen in objective outcomes such as 
Ashworth scores, and minor adverse effects such as dizziness 
commonly occur. Serious adverse effects on cognition or 
psychopathology have not been seen, but studies have been 
limited to several months, limiting ability to assess long-term   
effects.123
Cognitive impairment has been found to occur in at least 
50% of MS patients; depression can contribute in some 
patients and is treated with antidepressants. Pharmacotherapy 
for cognitive dysfunction has primarily centered on neuroac-
tive agents used in the treatment of Alzheimer’s disease.104 
However, studies of cholinesterase inhibitors in MS patients 
have produced mixed results, prompting recent research 
of different pharmacologic approaches.124,125 Morrow et al 
reported on the effects of l-amphetamine in 136 MS patients 
with documented cognitive deficits randomized in a 2:1 ratio 
to active drug or placebo at 33 centers in the United States. 
After ∼1 month of therapy, patients receiving l-amphetamine 
saw no significant benefit in the two primary outcomes 
of Symbol Digit Modalities Test (P = 0.506) or Subject 
Global Assessment of Change from baseline (P = 0.879), 
but significant benefits with active drug were determined for 
secondary measures of auditory/visual learning and visual/
special memory.126 A recent double-blind, randomized trial 
by Lovera et al compared 16 weeks of the usual dosage 
of the NDMA glutamine receptor antagonist memantine 
to placebo in 114 MS patients with cognitive deficits but 
without depression. No differences were seen in the primary 
outcome for changes from baseline for the PASAT and 
California Verbal Learning Test-II (CVLT-II), Long Delay 
Free Recall (LDFR), or in several secondary neuropsychiatric   
measures.127
Conclusion
Agents in Phase III trials that have been shown to reduce 
relapse rates and decrease the burden of CNS lesions 
as detected by MRI include fingolimod, alemtuzumab, 
cladribine, and rituximab. Additionally, several agents such 
as teriflunomide, daclizumab, laquinimod, and fumarate 
have reported promising results in Phase II trials. Quality of 
life concerns for patients with MS are also at the forefront 
of current research, and advancements in managing spas-
ticity, ambulation, and cognition are also being realized. 
Despite the promise of new agents and developments in 
understanding the disease progression and initial inflamma-
tory insult, the long-term risks of new agents remain largely 
unknown. Research continues to generate novel therapies for 
modifying MS and aiding in management of common MS   
symptoms.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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